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ABSTRACT
Tuberculosis (TB) is a major public-health problem in India, having the highest number of incident and 
multidrug-resistant (MDR) TB cases. The study was carried out to appraise the prevalence of first-line anti-
TB drug resistance in Mycobacterium tuberculosis (MTB) and its patterns among different types of TB patients 
from different settings in a province of North India. Of 3,704 clinical specimens, 345 (9.3%) were culture-
positive, and drug-susceptibility testing was carried out for 301 MTB strains. A high level of primary and 
acquired drug resistance of MTB was observed in the region studied, with weighted mean of 10.5% 
and 28.08%, 12.81% and 29.72%, 17.12% and 29.94%, 11.97% and 27.84%, and 10.74% and 23.54% 
for rifampicin, isoniazid, streptomycin, ethambutol-resistant and MDR cases respectively. Drug resistance 
was significantly higher in pulmonary (p=0.014) and acquired drug-resistant TB cases (p<0.001). Any drug 
resistance (p=0.002) and MDR TB were significantly (p=0.009) associated with HIV-seropositive cases. An 
urgent plan is needed to continuously monitor the transmission trends of drug-resistant strains, espe-
cially MDR-TB strains, in the region.  
Key words: Acquired immunodeficiency syndrome; Antitubercular drugs; Diabetes; Drug resistance; HIV; 
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INTRODUCTION
India has the highest number of the incident tuber-
culosis (TB) and multidrug-resistant (MDR) TB cases; 
yet the factors contributing to emergence, spread, 
and containment of TB are not well-estimated. TB 
is a major public-health problem, particularly in de-
veloping nations where the prevalence of infection 
is 40% (1). The incidence has been accelerated by the 
HIV epidemic, the appearance of new genotypes, 
multidrug-resistant and extensively drug-resistant 
(XDR) strains of Mycobacterium tuberculosis (MTB). 
Development of drug resistance in the population 
has increased the possibility that TB may once 
again become an incurable disease. 
In 2008, there were 9.4 million new TB cases (in-
cluding 3.6 million women and 1.4 million cases 
among people living with HIV) throughout the 
world. Approximately 1.8 million people died from 
TB in 2008, of whom 500,000 were HIV-infected 
people. HIV-positive people co-infected with TB are 
20-40 times more likely to develop active TB than 
people without HIV infection living in the same 
country (2).
In 2008, most of the estimated number of TB cases 
occurred in Asia (55%) and Africa (30%). The five 
countries ranking first to fifth in terms of total 
numbers of incident cases were India (1.6-2.4 mil-
lion), China (1-1.6 million), South Africa (0.38-
0.57 million), Nigeria (0.37-0.55 million), and 
Indonesia (0.34-0.52 million). An estimated 35% 
of TB cases worldwide were found in India and 
China alone. There were an estimated 0.5 million 
cases of MDR-TB worldwide in 2007. The countries 
that ranked first to fifth in terms of total numbers 
of MDR-TB cases in 2007 were India (n=1,31,000), 
China (n=1,12,000), the Russian Federation (n= 
43,000), South Africa (n=16,000), and Bangladesh 
(n=15,000). To meet the targets set in the global 
plan, diagnosis and treatment of MDR-TB need to 
be rapidly scaled up, especially in the three coun-
tries that account for 57% of global cases: China, 
India, and the Russian Federation (3).Gupta A et al.
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The incidence of TB is the greatest among those 
with impaired immunity, such as people with HIV 
infection and diabetes. HIV is a very important risk 
factor that enhances the progression of active TB 
in people with latent TB infection (4). The lifetime 
risk of TB in immunocompetent persons is 5-10% 
but, in HIV-positive individuals, there is a 5-15% 
annual risk of developing active TB disease (5). Dia-
betes mellitus (DM), a metabolic disorder, weakens 
the immune system. The incidence of TB, particu-
larly pulmonary TB (PTB), is higher in diabetics 
compared to non-diabetics (6).
Resistance in cultures from patients for which treat-
ment had been administered for <1 month or not at 
all is known as primary drug resistance (PDR) while 
that from patients with one or more previous TB 
treatment episodes (for at least one or more than 
one month), including those with treatment fail-
ures and relapse, is called acquired drug resistance 
(ADR) (7). MDR-TB is defined as resistance to the two 
main first-line anti-TB drugs—isoniazid (INH) and 
rifampicin (RIF)—with or without resistance to any 
other drugs. XDR-TB is a form of TB caused by bacte-
ria that are resistant to most effective anti-TB drugs 
and defined as resistance to at least RIF and INH 
and to any member of the quinolone family and 
at least one of the following second-line anti-TB in-
jectable aminoglycosides: kanamycin, capreomycin, 
or amikacin (8). Both primary drug resistance and 
acquired drug resistance contribute to MDR/XDR 
TB (9). 
MDR-TB is an emerging problem in the world. Sev-
eral outbreaks of MDR-TB have recently been re-
ported. The prevalence of MDR-TB in India is 3.4% 
in primary (new) TB cases and 25% in acquired 
cases (10). In the second global report of the World 
Health Organization/International Union Against 
Tuberculosis and Lung Disease followed in 2000 in 
58 countries, the median prevalence of resistance 
to at least one drug among new TB cases was 10.7% 
(range 2-36%), and that of MDR-TB was 1% (range 
0-14%). In the previously-treated cases, the me-
dian prevalence of resistance to at least one drug 
was 23% (range 0-94%) and that of MDR-TB was 
9% (range 0-48%) (11,12).
Surveillance data on primary and acquired drug re-
sistance in MTB are important to design TB-control 
programmes. Escalating HIV infection and diabetes 
and negligence in TB control have caused an in-
crease in the incidence of TB over the last decade in 
both developing and developed countries (13,14). 
Moreover, several other factors, such as home-
lessness, poverty, lack of infrastructure in public 
health, and inadequate access to health services 
have played an important role in worsening the 
situation. 
In the present study, we aimed at determining the 
prevalence of first-line anti-TB drug resistance and 
its patterns in MTB isolated from different types of 
TB patients of North India.
MATERIALS AND METHODS
Study settings
The study was conducted at the Department of 
Microbiology, Institute of Medical Sciences, Bana-
ras Hindu University (BHU). Sir Sundar Lal Hospital, 
a tertiary-care hospital of BHU, has a vast catch-
ment area, this being the only tertiary-care hospital 
in north-eastern Uttar Pradesh (UP) providing med-
ical coverage to a population of over 15 crore 
in eastern UP, western Bihar, and adjoining areas of 
Madhya Pradesh and Nepal. Our mycobacterio-
logy laboratory is equipped to perform culture 
and drug-sensitivity testing (DST) for MTB. The 
sputum samples were collected from selected TB 
centres based on the maximum frequency of 
patients attending those centres. These were De-
partment of TB and Respiratory Disease and 
antiretroviral therapy (ART) centres of Sir Sundar 
Lal Hospital of BHU, Shree Shiv Prasad Gupta Dis-
trict Hospital, Kabir Chaura (a secondary-care 
centre), Swami Vivekanand Smarak Rajkiya Chikit-
salaya, Bhelupura (a primary healthcare unit), and 
Integrated Counselling and Testing Centre (ICTC) 
of the Department of Microbiology, Institute of 
Medical Sciences, BHU (a tertiary-care centre). The 
duration of the study was 25 months from Janu-
ary 2008 to January 2010. It included samples 
from both inpatients and outpatients. 
Study subjects
The study included TB patients with or without 
any other additional complication, such as HIV-se-
ropositivity/diabetes (based on their previous and 
current medical records). Information was collect-
ed from the medical files and compliance charts on 
demographic characteristics of patients, radiologi-
cal studies, and sputum mycobacteriologic studies.
Collection and transportation of specimens
Specimens were collected in disposable wide-
mouthed containers which were made of clear 
thin plastic, unbreakable and leak-proof material. 
These were placed in a box which could withstand 
leakage of contents, shocks, and other conditions 
incident to ordinary handling practices. Those box-
es were immediately transported to the laboratory.Gupta A et al. Prevalence of drug-resistant TB in northern India
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Specimens/mycobacterial strains
Both pulmonary and extra-pulmonary specimens   
from 3,704 clinically-suspected TB patients, i.e.   
sputum, bronchoalveolar lavage (BAL), gastric fluid 
and cerebrospinal fluid (CSF), endometrial tissues, 
pus, fine-needle aspirate, urine, pleural fluid, lymph-
node biopsy, ascitic fluid, pericardial fluid, knee flu-
id, and sinus discharge, were collected and used for 
preparing smear. The smears were subjected to acid 
fast stain by Ziehl-Neelsen method and examined 
by light microscopy at 100x oil-immersion objec-
tive. Sputum, BAL, pus and urine specimens were   
decontaminated by modified Petroff’s method us-
ing 4% NaOH (15,16) while decontamination of 
other specimens was not needed as those were col-
lected aseptically. All the specimens were concen-
trated by centrifugation at 3,200 × g for 20 min-
utes. The supernatant was discarded, and a part of 
the sediment was used for culture. Isolated cultures 
were characterized by certain biochemical tests, 
such as heat-stable catalase, niacin accumulation, 
and susceptibility to p-nitro benzoic acid (PNB) 
(17). 
Drug-sensitivity testing
Isolated MTB strains were subjected to indirect DST 
by proportion method (PM), the gold standard for 
DST of MTB. Conventional Lowenstein-Jensen (LJ) 
medium was prepared as described earlier (15). DST 
was carried out on LJ medium according to the 
standard procedures of the laboratory, with the re-
commended critical concentrations of 40 µg/mL for 
RIF, 0.2 µg/mL for INH, 2 µg/mL for ethambutol 
(EMB), and 4 µg/mL for streptomycin (STR) (15,18). 
In brief, bacterial suspension for DST was prepared 
in the concentration of 1 mg/mL suspension (S1 
suspension). S1 was further diluted 10-fold to ob-
tain S2-S4. S1-S4 bacterial concentrations were res- 
pectively inoculated into drug-free and drug-con-
taining LJ slopes using a 3-mm internal diameter 
wire-loop and incubated at 37 °C. Growth was re-
corded at 28 days and at 42 days as follows: +++ for 
confluent growth, ++ for more than 100 colonies, 
and 1-100 actual numbers of colonies. Susceptibili- 
ty or resistance was recorded when the proportion 
of bacteria in drug-containing medium to that of 
drug-free medium was <1 or ≥1 respectively. 
Laboratory quality control/quality assurance 
H37Rv (ATCC 27294) and a known MDR strain 
were used as controls. The laboratory supervisor 
examined the DST results. DST of 69 MTB strains 
(23%), which showed contamination, was repeat-
ed.
Analysis of data
The proportion of resistant isolates per setting was 
calculated. The weighted mean for each setting was 
calculated by multiplying the number of resistant 
cases in each setting and the weighted case (number 
of cases in each setting divided by the total number 
of cases) of the same setting. Other results were ana- 
lyzed with the SPSS software (version 12.0.1) (SPSS 
Inc., Chicago, IL, USA). The features of two groups 
were compared using the Z-test and of three groups 
by chi-square (χ2) test for the assessment of statisti-
cal significance. A p value of <0.05 was considered 
significant.
Ethical issues
The study was approved by the ethical committee 
of the institution.
RESULTS
Pulmonary (85.56%) and  extra-pulmonary (14.44%) 
specimens from 3,704 clinically-suspected TB pa-
tients  were  collected.  Statistically,  a  sample-size 
of approximately 3,704 was required for investiga-
tion of the prevalence of TB and MDR-TB in our 
region.
Of the 3,704 specimens, 345 (9.3%) were culture-
positive, of which 333 (96.52%) were tubercle, and 
12 (3.48%) were non-tubercle bacilli. Of the 333 
MTB isolates, DST of only 301 was performed. Due 
to contamination, we were unable to read the DST 
results of 32 culture-positive MTB isolates. Further, 
the sufficient extent of MTB growth was not avail-
able to repeat DST.
Drug resistance 
DST for all the four first-line anti-TB drugs, i.e. 
RIF, INH, STR, and EMB,  was performed. There were 
no significant differences between the resistance 
rates of STR (46.84%), INH (42.83%), RIF (38.53%), 
EMB (39.20%), and MDR (34.55%) (Fig.).
Primary, acquired and total drug resistance levels 
for RIF, INH, STR, and EMB are shown in Table 1. 
Almost similar differences were found in resistance 
proportions for the individual drug among all 
four settings. On average, resistance proportions in 
new and acquired resistant cases were the high-
est for STR (17.12% and 29.94% respectively) and 
INH (12.81% and 29.72% respectively) whereas for 
EMB and RIF, these were 11.97% and 10.55%, and 
27.84% and 28.08% respectively. 
Some differences were observed in the percentage 
of MDR prevalence. Among the new cases, it was Gupta A et al.
JHPN 586
Prevalence of drug-resistant TB in northern India
the highest (25%) in the cases from the first and 
third settings, followed by the fourth (15.0%) and 
second (14.28%) settings. In the acquired cases, it 
was the highest in the second setting (68.82%), fol-
lowed by the fourth (66.66%) and third (50.0%) 
settings whereas it was the lowest in the first one 
(45.45%) (Table 1).
Of the 301 cases studied, 199 (66.11%) were male, 
and 102 (33.88%) were female. Of  the 199 males, 
104 (61.53%) showed resistance to one or more 
than one tested anti-TB drugs whereas 65 (38.46%) 
of the 102 females showed drug-resistant TB. The 
mean age at diagnosis of drug-resistant TB was 33 
(range 4-75) years. Most cases of PTB were aged 
21-40 years. Extra-pulmonary TB was documented 
mostly in the age-group of <10 years. Most com-
mon extra-pulmonary TB found was tubercular 
lymphadenitis (17.69%), followed by pleural TB 
(13.85%).
In the present study, resistance to any drug and 
multidrug resistance were analyzed against sex, 
age, nature of specimen, and type of resistance. 
Resistance was significantly higher in pulmonary 
(p=0.014) and ADR-TB cases (p<0.001). How-
ever, resistance was not significantly associated 
with any age-group or sex. In addition, MDR-TB 
was significantly higher only in the case of ADR-TB 
(p=0.0019) (Table 2).
Of the 301 cases for which DST was performed, 269 
(89.37%) were both smear- and culture-positive 
whereas 32 (10.63%) cases were smear-negative but 
culture-positive. Of the 269 cases, which were both 
smear- and culture-positive, 151 (56.13%) were 
resistant to one or more tested anti-TB drugs. Of 
the 32 culture-positive cases, 18 (10.65%) were re-
sistant to one or more tested anti-TB drugs. The 
prevalence of resistance to any drug and multid-
rugs was analyzed for the same categories and had 
no significant association (Table 3).
Of the 3,704 specimens, 82 (2.21%) were HIV-sero-
positive. Of the 82 HIV-seropositive specimens, 37 
(45.12%) were culture-positive. Of the 37 culture-
positive specimens, susceptibility testing was done 
for 32 specimens. By excluding the diabetic cases, 
the association of HIV and TB was analyzed in 294 
(97.67%) cases. Of the 294 cases, 32 (10.88%) con-
secutive patients of TB were co-infected with HIV 
while 262 (89.12%) were only culture-positive for 
TB. Of the 32 HIV-TB cases, 26 (15.85%) were resist-
ant to one or more tested anti-TB drugs, of which 
10 (10.0%) were MDR. The prevalence of resistance 
to any drug and multidrug resistance was analyzed 
for the above two categories, and significant asso-
ciations were observed (Table 3).
Of the 3,704 specimens, 26 (0.70%) cases were dia-
betics, along with smear-positivity. Of the 26 cases, 
only nine (34.62%) were culture-positive, and sus-
ceptibility testing was done for eight strains. By 
excluding the HIV cases, the association between 
diabetes and TB was analyzed only in 270 (89.70%) 
cases. Of the 270 cases, eight (2.96%) consecutive 
patients of TB had diabetes-related complication. 
Of the eight diabetic-TB cases, six were resistant 
to one or more anti-TB drugs, in which five were 
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MDR. The prevalence of resistance to any drug and 
multidrug resistance was analyzed for the above 
two categories, and no significant association was 
found between them (Table 3).
DISCUSSION
DST is performed for several purposes, such as in 
relapse or retreatment cases, to change the drug 
regimen when resistance is suspected, or for un-
dertaking drug resistance surveillance studies in a 
region/country. 
Considering the resistance in all the four settings, 
on average, it was the highest for STR in new 
(17.12%) and in previously-treated cases (29.94%) 
while it was the lowest for RIF (10.55%) in new cas-
es and for EMB (27.84%) in the previously-treated 
cases (Table 1). The same results were observed in 
a study in Russia, in which the highest resistance 
was observed for STR in new and previously-treated 
cases with 40.4% and 66.7% respectively whereas 
resistance to RIF and EMB was the lowest in new 
cases (13.5%) and in the previously-treated cases 
(60.0%) respectively (19). These observations clear-
ly demon-strate the significance of critical monitor-
ing of drug resistance pattern in a set-up, par-
ticularly where there is a high prevalence of drug 
resistance.
According to the World Health Organization 
(WHO), India is number one in terms of the preva-
lence of TB, and 3.4 million (17%) TB patients have 
developed multidrug resistance. Drug resistance 
surveys in Gujarat and Maharashtra (2005-2006) 
showed the prevalence of MDR-TB to be almost 3% 
among primary and 12-18% in previously-treated 
cases. It is estimated that the prevalence of MDR-TB 
may be three times greater than its incidence (20). 
MDR-TB in retreatment patients varies from 30% to 
80% in different regions (21). In this study, on aver-
age, the resistance proportion of MDR-TB was high, 
with 34.61% among all the cases, 19.82% showing 
primary resistance, and 57.73% acquired resistance. 
We report a high rate of multidrug resistance in 
both newly-infected and previously-treated cases, 
which is in good agreement with earlier observa-
tions reported from India and some former Soviet 
Union countries (22-24). Among the new cases, 
the percentage of MDR prevalence was the highest 
(25%) in the cases from the first and third settings. 
In the case of the first setting, it could be because 
all the extra-pulmonary TB cases were from the 
same setting. In the third setting, being a primary 
healthcare centre, the prevalence of MDR-TB was 
the highest in new cases. In the acquired cases, it 
was the highest in the second setting (68.82%), fol-
lowed by the fourth setting (66.66%). The second 
setting is a tertiary referral hospital, and the fourth 
setting is a secondary healthcare centre (district TB 
centre, Varanasi, India) where patients with more 
serious conditions may have presented, resulting 
in the highest number of acquired resistant cases. 
This study noted that the prevalence of MDR-TB 
was not significantly associated with age, sex, pul-
monary TB, or extra-pulmonary TB. 
Furthermore, resistance to any drug was significant- 
ly higher in the previously-treated patients (Table 2). 
The relationship between history of receiving anti-
TB treatment and drug resistance has been clearly 
Table 2. Characteristics of tuberculosis patients for whom drug-susceptibility testing was done
Variable No. (%)
Drug resistance
No. (%)
p value
MDR-TB
 No. (%)
p value
Total cases 301 169 104
Sex
   Male 
   Female
199 (66.11)
102 (33.88)
104 (61.53)
65 (38.46)
0.0578
63 (60.57)
41 (39.42)
0.7452
Age (years)
   ≤15 
  16-65 
  >65 
14 (4.65)
280 (93.02)
7 (2.32)
11 (6.51)
155 (91.71)
3 (1.77)
0.179
7 (6.73)
96 (92.30)
1 (0.96%)
0.595
Nature of specimen
   Pulmonary 
   Extra-pulmonary 
288 (95.68)
13 (4.32)
166 (98.22)
3 (1.78)
0.0140
103 (99.03)
1 (0.96)
0.311
Type of resistance
   Primary resistance 
   Acquired resistance       
180 (59.80)
121 (40.19)
71 (42.01)
98 (57.98)
<0.001
34 (32.69)
70 (67.30)
0.0019
DST=Drug-susceptibility testing; MDR=Multidrug-resistantGupta A et al. Prevalence of drug-resistant TB in northern India
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described in several studies (12,25,26). A significant 
difference in drug resistance between the new and 
the retreatment patients confirms the inefficiency 
of TB-control programmes. The use of irregular/im-
proper anti-TB drugs during recent years has led 
to accumulation and multiplication of resistant 
strains. Notably, resistance to RIF, which did not 
show an increase in the new cases, was significantly 
elevated in the retreated cases. This reveals the fact 
that, with irregular treatment and in the presence 
of INH resistance, virtual monotherapy results in 
resistance to other agents as well (27). 
The proportions of drug resistance among the new 
and the previously-treated TB cases are important 
indicators for epidemiology of TB. The level of 
initial drug resistance is said to be an epidemio-
logical marker to assess the success of the National 
TB Programme. This also influences the design of 
regimens to be employed and policy decisions. 
In a well-functioning TB-control programme, a 
low level of mistake in treatment can increase the 
probability of high resistance level among acquired 
resistant cases because drug resistance is a strong 
risk factor for recurrent TB. However, if a good TB-
control programme is in place, proportion of the 
previously-treated patients among all TB patients 
should be low.
Overall, we found that the drug resistance to STR 
and INH in the new and the previously-treated cases 
was more frequent compared to other agents. Simi-
larly, the first, second and third rounds of the WHO 
Global Projects and similar studies in Iran (eight 
years of surveillance) and Thailand have shown 
that the resistance to the above-mentioned agents 
was more common compared to the resistance to 
other first-line drugs (1,12,25,28). In general, resis-
tance to STR and INH has been reported to be high-
er than EMB and RIF all over the world (29). How-
ever, other patterns of anti-TB resistance also exist. 
In a 15-year surveillance in Saudi Arabia, resistance 
to INH and EMB was more frequent than to other 
first-line drugs (30) whereas, in a study in Dhaka, 
Bangladesh, resistance to INH and RIF was found 
to be more frequent (31). Moreover, a prospec-
tive study set in the National Masan Tuberculosis 
Hospital in Masan, Republic of Korea, reported the 
enrollment and treatment of 19 patients with well-
localized, cavitary pulmonary MDR-TB or XDR-TB 
with anti-TB therapy consisting of INH, RIF, EMB, 
pyrazinamide (Z), and STR. All recovered isolates 
of MTB were resistant to INH and RIF. Resistance 
to the first-line agents—EMB, STR, and Z—was ob-
served in 73.7%, 36.8%, and 26.3% of isolates res- 
pectively (32).
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In the present study, the prevalence of HIV in TB 
patients was 10.72% (37/345). A study in sub-Sa-
haran Africa has recorded the HIV-seroprevalence 
rates of 50-70% in patients with TB (33). However, 
India has reported the HIV-seropositivity rates of 
0.4-20.1% (34). This highlights the importance of 
effective guidelines developed by the WHO to con-
trol the emergence of TB co-infection in HIV/AIDS. 
In our study, resistance to any drug was significant-
ly higher in the HIV-infected patients compared 
to the non-HIV patients. The same trend was also 
observed in the case of MDR-TB. According to the 
literature, infections with HIV and alcohol-abuse 
are important risk factors for the development of 
TB and the appearance of drug resistance in MTB 
infection (35).
The incidence of TB is higher in diabetics compared 
to the general population. The risk of developing 
an active TB infection is 3-7 times greater in per-
sons with diabetes than non-diabetics (36). Each 
year, India accounts for one-fifth of the newly-
diagnosed TB cases worldwide, of which almost 
half have diabetes (37). The prevalence of diabetes 
worldwide is close to 10%, and the relative risk of 
TB varies from 3% to >8% depending on the study 
(38). Furthermore, Stevenson et al. concluded that, 
in India, diabetes makes a substantial contribution 
to the burden of incident TB (39), and the associa-
tion is particularly strong for the infectious form of 
TB. However, in our study, there was no significant 
relationship between TB and diabetes, which might 
be due to the enrollment of a low number of cases. 
The overall importance of diabetes as a risk factor 
for TB is still largely unidentified, although a recent 
study in Mexico concluded that, in the population 
studied, 25% of pulmonary TB was attributable to 
diabetes (36).
Our centre is an important referral centre in North 
India. However, our data may not necessarily be 
representative of the national population, especial-
ly with regard to new cases because only patients 
with more serious conditions may have presented 
to our centre. However, its findings will be indica-
tive of the local population-related information for 
the previously-treated patients. A nationwide sur-
vey of drug resistance is required to achieve a more 
accurate assessment, management, and control of 
this deadly infectious disease.
A strong and cost-effective TB-control programme 
can reduce the incidence of drug resistance in the 
community. Some modifications should be made 
in running of the TB-control programme. For ex-
ample, routine quality-assured DST for those pa-
tients who are at a high risk of resistance, especially 
failure cases, and those treated with second-line 
drugs should be done. In addition, we felt that 
the  screening  of  all  HIV/diabetic  patients  for  TB 
and all TB patients for HIV and diabetes will help 
detect co-infected patients who require treatment 
for both the infections. This can be done by a good 
coordination and communication between TB and 
AIDS/diabetes-control programmes. These have 
potentially serious implications for TB control, 
and it must become a priority to use the existing 
knowledge about the association of TB with HIV/
diabetes patients to initiate focused and coordinat-
ed actions, including new research in parts of the 
world where diabetes/HIV is epidemic and TB is 
endemic to properly inform public health and 
clinical practice. Standard chemotherapy with in-
dividualized drug resistance therapy, guided by 
conventional DST, might not be sufficient to con-
trol drug-resistant TB in northern India. Therefore, 
there is an urgent requirement of a plan to expand 
appropriate diagnostic and treatment services for 
patients with drug-resistant TB, especially MDR-TB, 
with or without having any additional complica-
tions, such as HIV/diabetes, throughout India and 
the world.
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